Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1981 1
1983 1
1985 2
1986 1
1988 3
1989 3
1990 6
1991 4
1993 1
1994 1
1995 3
1996 6
1997 5
1998 9
1999 4
2000 2
2001 4
2002 5
2003 5
2004 5
2005 5
2006 1
2007 6
2008 9
2009 8
2010 8
2011 12
2012 13
2013 12
2014 23
2015 14
2016 21
2017 20
2018 15
2019 14
2020 28
2021 17
2022 12
2023 8
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

288 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Renal hypomagnesemia 2"
Page 1
Hungry bone syndrome.
Jain N, Reilly RF. Jain N, et al. Curr Opin Nephrol Hypertens. 2017 Jul;26(4):250-255. doi: 10.1097/MNH.0000000000000327. Curr Opin Nephrol Hypertens. 2017. PMID: 28375869 Review.
A fall in serum calcium concentration is common postparathyroidectomy in patients with hyperparathyroidism, which usually resolves in 2-4 days. A severe drop in serum total calcium concentration less than 2.1 mmol/L and/or prolonged hypocalcemia for more than 4 days …
A fall in serum calcium concentration is common postparathyroidectomy in patients with hyperparathyroidism, which usually resolves in 2 …
The emerging role of magnesium in CKD.
Sakaguchi Y. Sakaguchi Y. Clin Exp Nephrol. 2022 May;26(5):379-384. doi: 10.1007/s10157-022-02182-4. Epub 2022 Jan 25. Clin Exp Nephrol. 2022. PMID: 35076791 Free PMC article. Review.
Increasing evidence has suggested a clinical relevance of magnesium in the context of vascular calcification and mortality among patients with CKD. Hypomagnesemia is not rare among non-dialysis CKD patients despite their decreased glomerular filtration rates; the prevalenc …
Increasing evidence has suggested a clinical relevance of magnesium in the context of vascular calcification and mortality among patients wi …
Risk factors for QTc-prolongation: systematic review of the evidence.
Vandael E, Vandenberk B, Vandenberghe J, Willems R, Foulon V. Vandael E, et al. Int J Clin Pharm. 2017 Feb;39(1):16-25. doi: 10.1007/s11096-016-0414-2. Epub 2016 Dec 23. Int J Clin Pharm. 2017. PMID: 28012118 Review.
Little or no evidence was found for hyperlipidemia, the use of digoxin or statins, neurological disorders, diabetes, renal failure, depression, alcohol abuse, heart rate, pulmonary disorders, hormone replacement therapy, hypomagnesemia, history of a prolonged QTc-in …
Little or no evidence was found for hyperlipidemia, the use of digoxin or statins, neurological disorders, diabetes, renal failure, d …
AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.
Wang B, Bonkovsky HL, Lim JK, Balwani M. Wang B, et al. Gastroenterology. 2023 Mar;164(3):484-491. doi: 10.1053/j.gastro.2022.11.034. Epub 2023 Jan 13. Gastroenterology. 2023. PMID: 36642627 Free PMC article. Review.
AHP is also associated with chronic symptoms and long-term risk of systemic arterial hypertension, chronic renal and liver disease, and hepatocellular carcinoma. Patients who have recurrent acute attacks (4 or more per year) should be considered for prophylactic therapy wi …
AHP is also associated with chronic symptoms and long-term risk of systemic arterial hypertension, chronic renal and liver disease, a …
Proton Pump Inhibitors and the Kidney: Implications of Current Evidence for Clinical Practice and When and How to Deprescribe.
Al-Aly Z, Maddukuri G, Xie Y. Al-Aly Z, et al. Am J Kidney Dis. 2020 Apr;75(4):497-507. doi: 10.1053/j.ajkd.2019.07.012. Epub 2019 Oct 10. Am J Kidney Dis. 2020. PMID: 31606235 Review.
Proton pump inhibitors (PPIs), long thought to be safe, are associated with a number of nonkidney adverse health outcomes and several untoward kidney outcomes, including hypomagnesemia, acute kidney injury, acute interstitial nephritis, incident chronic kidney disease, kid …
Proton pump inhibitors (PPIs), long thought to be safe, are associated with a number of nonkidney adverse health outcomes and several untowa …
Hypomagnesaemia.
[No authors listed] [No authors listed] Drug Ther Bull. 2013 Mar;51(3):33-6. doi: 10.1136/dtb.2013.1.0169. Drug Ther Bull. 2013. PMID: 23482516 Review.
Magnesium plays an important role in the body as a cofactor for DNA and protein synthesis, oxidative phosphorylation, neuromuscular excitability, enzyme activity and regulation of parathyroid hormone (PTH) secretion.1 The regulation of plasma magnesium concentration is balanced b …
Magnesium plays an important role in the body as a cofactor for DNA and protein synthesis, oxidative phosphorylation, neuromuscular excitabi …
Association of magnesium sulfate use with mortality in critically ill patients with sepsis: a retrospective propensity score-matched cohort study.
Gu WJ, Duan XJ, Liu XZ, Cen Y, Tao LY, Lyu J, Yin HY. Gu WJ, et al. Br J Anaesth. 2023 Nov;131(5):861-870. doi: 10.1016/j.bja.2023.08.005. Epub 2023 Sep 7. Br J Anaesth. 2023. PMID: 37684164 Free article.
RESULTS: The pre-matched and propensity score-matched cohorts included 10 999 and 6052 patients, respectively. In the PSM analysis, 28-day all-cause mortality rate was 20.2% (611/3026) in the magnesium sulfate use group and 25.0% (757/3026) in the no use group. ...Lower mo …
RESULTS: The pre-matched and propensity score-matched cohorts included 10 999 and 6052 patients, respectively. In the PSM analysis, 28-day a …
Hypomagnesemia in the Cancer Patient.
Workeneh BT, Uppal NN, Jhaveri KD, Rondon-Berrios H. Workeneh BT, et al. Kidney360. 2020 Nov 11;2(1):154-166. doi: 10.34067/KID.0005622020. eCollection 2021 Jan 28. Kidney360. 2020. PMID: 35368816 Free PMC article. Review.
Patients with cancer are at risk for opportunistic infections, frequently experience cardiovascular complications, and often receive classes of medications that cause or exacerbate hypomagnesemia. Also, cancer-specific therapies are responsible for hypomagnesemia, i …
Patients with cancer are at risk for opportunistic infections, frequently experience cardiovascular complications, and often receive classes …
Obesity and hypomagnesemia.
Guerrero-Romero F, Flores-García A, Saldaña-Guerrero S, Simental-Mendía LE, Rodríguez-Morán M. Guerrero-Romero F, et al. Eur J Intern Med. 2016 Oct;34:29-33. doi: 10.1016/j.ejim.2016.06.015. Epub 2016 Jun 25. Eur J Intern Med. 2016. PMID: 27353277
Extreme exercise, chronic diarrhea, alcohol intake, use of diuretics, smoking, oral magnesium supplementation, diabetes, malnutrition, hypertension, liver disease, thyroid disorders, and renal damage were exclusion criteria. Based in the Body Mass Index (BMI), body weight …
Extreme exercise, chronic diarrhea, alcohol intake, use of diuretics, smoking, oral magnesium supplementation, diabetes, malnutrition, hyper …
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DYC, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ; METEOR investigators. Choueiri TK, et al. Lancet Oncol. 2016 Jul;17(7):917-927. doi: 10.1016/S1470-2045(16)30107-3. Epub 2016 Jun 5. Lancet Oncol. 2016. PMID: 27279544 Clinical Trial.
The randomised phase 3 METEOR trial compared the efficacy and safety of cabozantinib versus the mTOR inhibitor everolimus in patients with advanced renal cell carcinoma who progressed after previous VEGFR tyrosine-kinase inhibitor treatment. ...The most common grade 3 or 4 …
The randomised phase 3 METEOR trial compared the efficacy and safety of cabozantinib versus the mTOR inhibitor everolimus in patients with a …
288 results